Advancing cardiovascular research

Chest

Volumn 141, Issue 2, 2012, Pages 500-505

  Lauer, Michael S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; AGING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL RESEARCH; CONGENITAL HEART DISEASE; DEGENERATIVE DISEASE; DISABILITY; EPIDEMIC; ETHNICITY; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL TECHNOLOGY; MORBIDITY; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STRUCTURAL HEART DISEASE; SUDDEN DEATH; UNITED STATES; VALVULAR HEART DISEASE;

EID: 84856756626     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2521     Document Type: Article

References (58)

1. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920-927. (Pubitemid 44315984)
2. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-2165.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
4. Collins FS. Research agenda. Opportunities for research and NIH. Science. 2010;327(5961):36-37.
5. Damani SB, Topol EJ. Emerging genomic applications in coronary artery disease. JACC Cardiovasc Interv. 2011;4(5):473-482.
6. Lynch AI, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299(3):296-307. (Pubitemid 351159366)
7. Epstein JA. Franklin H. Epstein Lecture. Cardiac development and implications for heart disease. N Engl J Med. 2010;363(17):1638-1647.
8. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation. 2010;121(8):1022-1032.
9. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol. 2009;6(6):419-429.
10. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908.
11. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363(15):1397-1409.
12. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.
13. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488-1491. (Pubitemid 46906617)
14. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491-1493. (Pubitemid 46906618)
15. McPherson R. Chromosome 9p21 and coronary artery disease. N Engl J Med. 2010;362(18):1736-1737.
16. Visel A, Zhu Y, May D, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464(7287):409-412.
17. Harismendy O, Notani D, Song X, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-g signalling response. Nature. 2011;470(7333):264-268.
18. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
19. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272.
20. Florez JC, Jablonski KA, Bayley N, et alDiabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355(3):241-250. (Pubitemid 44079339)
21. ParéG, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-1714.
22. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824):575-579. (Pubitemid 46683138)
23. van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219-234.
24. Sanz J, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2011;58(8):779-791.
25. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
26. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3(90):90cm17.
27. Lauer MS, Skarlatos S. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community. Circulation. 2010;121(7):929-933.
28. Garber AM. An uncertain future for cardiovascular drug development? N Engl J Med. 2009;360(12):1169-1171.
29. MoyéLA, Sayre SL, Westbrook L, et al. Oversight and management of a cell therapy clinical trial network: experience and lessons learned. Contemp Clin Trials. 2011;32(5):614-619.
30. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4):385-392.
31. Krumholz HM, Herrin J, Miller LE, et al. Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation. 2011;124(9):1038-1045.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [published correction appears in JAMA. 2004;291(18):2196, JAMA. 2003;289(2):178]. JAMA. 2002;288 (23):2981-2997.
33. Hochman JS, Lamas GA, Buller CE, et alOccluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355(23):2395-2407. (Pubitemid 44911017)
34. Stafford RS, Bartholomew LK, Cushman WC, et alALLHAT Collaborative Research Group. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med. 2010;170(10):851-858.
35. Deyell MW, Buller CE, Miller LH, et al. Impact of National Clinical Guideline Recommendations for Revascularization of Persistently Occluded Infarct-Related Arteries on Clinical Practice in the United States. Arch Intern Med. 2011. 171(18):1636-1643.
36. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med. 2010;2(37):37cm18.
37. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008;299(23):2789-2791. (Pubitemid 351846854)
38. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305(17):1769-1776.
39. Tang AS, Wells GA, Talajic M, et al; Resynchronization- Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385- 2395.
40. Wilber DJ, Pappone C, Neuzil P, et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333-340.
41. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
42. Smith CR, Leon MB, Mack MJ, et al PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-2198.
43. Iglehart JK. Health insurers and medical-imaging policy - a work in progress. N Engl J Med. 2009;360(10):1030-1037.
44. ACCORD Study Group; Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
45. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
46. ACCORD Study Group;Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
47. National Institutes of Health Clinical Center. Catheter ablation versus anti-arrhythmic drug therapy for atrial fibrillation trial (CABANA). NCT00911508. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health;2009. http://clinicaltrials.gov/ct2/show/NCT00911508. Updated December 2, 2011.
48. National Institutes of Health Clinical Center. PROspective multicenter imaging study for evaluation of chest pain (PROMISE). NCT01174550. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health;2010. http://clinicaltrials.gov/ct2/show/NCT01174550. Updated August 2, 2010.
49. National Institutes of Health Clinical Center. Multicenter study to rule out myocardial infarction by cardiac computed tomography (ROMICAT-II). NCT01084239. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health;2010. http://clinicaltrials.gov/ct2/show/NCT01084239. Updated May 16, 2011.
50. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301(8):831-841.
51. Califf RM, Harrington RA. American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy? J Am Coll Cardiol. 2011;58(7):677-680.
52. Marshall EC. Medicine. A bruising battle over lung scans. Science. 2008;320(5876):600-603.
53. National Lung Screening Trial Research Team;Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
54. Partridge EE, Mayer-Davis EJ, Sacco RL, Balch AJ. Creating a 21st century global health agenda: the General Assembly of the United Nations High Level Meeting on Non-Communicable Diseases. Circulation. 2011;123(25):3012-3014.
55. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124(3):314-323.
56. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816-823.
57. de Saint-Exupéry, A. The Wisdom of the Sands. New York, NY: Harcourt, Brace and Company;1950:155.
58. Shurin SB. Funding mechanisms and program management at the National Heart, Lung, and Blood Institute (NHLBI): confronting new challenges and exploring new opportunities [published online ahead of print August 25, 2011]. Blood. doi:10.1182/blood-2011-08-372367.